Feb 20, 2020 / 12:00PM GMT
Operator
Good day, and welcome come to the evobrutinib RMS update call. Today's conference is being recorded.
At this time, I would like to turn the conference over to Constantin Fest. Please go ahead, sir.
Constantin Fest - MERCK Kommanditgesellschaft auf Aktien - Head of IR
Thank you, Margaret. Yes. Dear ladies and gentlemen, a very warm welcome from my side. My name is Constantin Fest, Head of Investor Relations here at Merck, and I welcome you to this evobrutinib update call. It's great to have also here on this call,
Luciano Rossetti, our Global Head of Research and Development; and Rehan Verjee, our President of EMD Serono and Global Head of the Innovative Medicine Franchises.
In the next roughly 15 minutes, we would like to guide you through the key slides of this presentation and the following 15 to 20 minutes, we would be then happy to take all of your questions. As stated before, today the focus is on evobrutinib. And I would kindly ask you to reserve all your non-evobrutinib-related Merck questions for our earnings release Q4 and
Merck KGaA Evobrutinib (RMS) Update Call Transcript
Feb 20, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers